Florentina A Simader, Christopher A Rajkumar, Michael J Foley, Fiyyaz Ahmed-Jushuf, Shayna Chotai, Nina Bual, Arif Khokhar, Aisha Gohar, Ioannis Lampadakis, Sashiananthan Ganesananthan, Rachel H Pathimagaraj, Alexandra Nowbar, John R Davies, Tom R Keeble, Peter D O'Kane, Peter Haworth, Helen Routledge, Tushar Kotecha, James C Spratt, Rupert Williams, Sukhjinder S Nijjer, Sayan Sen, Nick Curzen, Manas Sinha, James P Howard, Graham Cole, Frank E Harrell, Darrel P Francis, Matthew J Shun-Shin, Rasha K Al-Lamee
BACKGROUND: Placebo-controlled evidence from ORBITA-2 found that percutaneous cutaneous intervention (PCI) in stable coronary artery disease with little or no antianginal medication relieved angina, but residual symptoms persisted in many. The reason for this was unclear. OBJECTIVES: ; This ORBITA-2 secondary analysis investigates the relationship between presenting symptoms and disease severity (anatomic, non-invasive, and invasive ischemia) and the ability of symptoms to predict the placebo-controlled efficacy of PCI...
May 10, 2024: Journal of the American College of Cardiology